These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 23870382)

  • 1. Immunomodulatory drugs (natalizumab), worsening of multiple sclerosis, rebound effect and similitude.
    Teixeira MZ
    Homeopathy; 2013 Jul; 102(3):215-24. PubMed ID: 23870382
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biological therapies (immunomodulatory drugs), worsening of psoriasis and rebound effect: new evidence of similitude.
    Teixeira MZ
    Homeopathy; 2016 Nov; 105(4):344-355. PubMed ID: 27914574
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antiresorptive drugs (bisphosphonates), atypical fractures and rebound effect: new evidence of similitude.
    Teixeira MZ
    Homeopathy; 2012 Oct; 101(4):231-42. PubMed ID: 23089219
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Delivery of healthy babies after natalizumab use for multiple sclerosis: a report of two cases.
    Hoevenaren IA; de Vries LC; Rijnders RJ; Lotgering FK
    Acta Neurol Scand; 2011 Jun; 123(6):430-3. PubMed ID: 21492099
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Natalizumab exerts direct signaling capacity and supports a pro-inflammatory phenotype in some patients with multiple sclerosis.
    Benkert TF; Dietz L; Hartmann EM; Leich E; Rosenwald A; Serfling E; Buttmann M; Berberich-Siebelt F
    PLoS One; 2012; 7(12):e52208. PubMed ID: 23284936
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recurrence or rebound of clinical relapses after discontinuation of natalizumab therapy in highly active MS patients.
    Sorensen PS; Koch-Henriksen N; Petersen T; Ravnborg M; Oturai A; Sellebjerg F
    J Neurol; 2014 Jun; 261(6):1170-7. PubMed ID: 24728334
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antidepressants, suicidality and rebound effect: evidence of similitude?
    Teixeira MZ
    Homeopathy; 2009 Apr; 98(2):114-21. PubMed ID: 19358965
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Immune reconstitution inflammatory syndrome and rebound syndrome in multiple sclerosis patients who stopped disease modification therapy: current understanding and a case report].
    Belova AN; Rasteryaeva MV; Zhulina NI; Belova EM; Boyko AN
    Zh Nevrol Psikhiatr Im S S Korsakova; 2017; 117(2. Vyp. 2):74-84. PubMed ID: 28617365
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Update on PML and PML-IRIS occurring in multiple sclerosis patients treated with natalizumab.
    Kleinschmidt-DeMasters BK; Miravalle A; Schowinsky J; Corboy J; Vollmer T
    J Neuropathol Exp Neurol; 2012 Jul; 71(7):604-17. PubMed ID: 22710964
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Natalizumab therapy for highly active pediatric multiple sclerosis.
    Kornek B; Aboul-Enein F; Rostasy K; Milos RI; Steiner I; Penzien J; Hellwig K; Pitarokoili K; Storm van's Gravesande K; Karenfort M; Blaschek A; Meyer A; Seidl R; Debelic D; Vass K; Prayer D; Kristoferitsch W; Bayas A
    JAMA Neurol; 2013 Apr; 70(4):469-75. PubMed ID: 23420110
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Natalizumab: an antibody targeting α4-integrin].
    Nakahara J
    Brain Nerve; 2014 Oct; 66(10):1149-58. PubMed ID: 25296869
    [TBL] [Abstract][Full Text] [Related]  

  • 12. What to expect after natalizumab cessation in a real-life setting.
    Salhofer-Polanyi S; Baumgartner A; Kraus J; Maida E; Schmied M; Leutmezer F
    Acta Neurol Scand; 2014 Aug; 130(2):97-102. PubMed ID: 24720783
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Natalizumab for multiple sclerosis: appraising risk versus benefit, a seemingly demanding tango.
    Gupta S; Weinstock-Guttman B
    Expert Opin Biol Ther; 2014 Jan; 14(1):115-26. PubMed ID: 24289270
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immune reconstitution inflammatory syndrome and natalizumab-Is it possible before removing the drug?
    Mulero P; Neri MJ; Rodriguez M; Arenillas JF; Téllez N
    Mult Scler Relat Disord; 2014 Sep; 3(5):659-61. PubMed ID: 26265277
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Natalizumab discontinuation is associated with a rebound of cognitive impairment in multiple sclerosis patients.
    Iaffaldano P; Viterbo RG; Trojano M
    J Neurol; 2016 Aug; 263(8):1620-5. PubMed ID: 27260295
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Increased disease activity in a case of multiple sclerosis after switching treatment from fingolimod to natalizumab].
    Akatani R; Chihara N; Katanazaka K; Ueda T; Sekiguchi K; Matsumoto R
    Rinsho Shinkeigaku; 2019 Aug; 59(8):536-540. PubMed ID: 31341130
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alemtuzumab as rescue therapy in case of multiple sclerosis rebound following Natalizumab break: Clinical case and literature review.
    Federle L; Puthenparampil M; Stenta G; Paolo G; Francesco P
    Mult Scler Relat Disord; 2019 May; 30():262-264. PubMed ID: 30851640
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cryptococcal meningitis in a multiple sclerosis patient taking natalizumab.
    Valenzuela RM; Pula JH; Garwacki D; Cotter J; Kattah JC
    J Neurol Sci; 2014 May; 340(1-2):109-11. PubMed ID: 24680560
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The discovery of natalizumab, a potent therapeutic for multiple sclerosis.
    Steinman L
    J Cell Biol; 2012 Oct; 199(3):413-6. PubMed ID: 23109666
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic use of the rebound effect of modern drugs: "New homeopathic medicines".
    Teixeira MZ
    Rev Assoc Med Bras (1992); 2017 Feb; 63(2):100-108. PubMed ID: 28355369
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.